EGYPTIAN INTERNATIONAL PHARMACEUTICALS (EIPICO)
PHAR

EGX

Current Price
EGP
EGP (%)
Price Upon Recommendation
50.26 EGP
Target Price from Recommendation

58.00 EGP

+15.40%
Holding Period

More than 12 months

Final Recommendation

Buy stock at the current price

Valid Until

April 18, 2026 at 12:00:00 AM

Risk Assessment

Medium

Confidence Score

78.00%

Potential Growth

18.40%

Investment Reason

PHAR is strategically positioned in Egypt's healthcare sector, benefiting from increased government healthcare spending and stable demand. Recent market resilience and alignment with EGX's upward trends indicate strong growth potential.

Overview
Recent Performance

PHAR has maintained steady volume with a 4.2% YTD gain, supported by sector tailwinds and EGX's 2024 momentum .

Economic Factors

Egypt's healthcare sector growth (6% CAGR), EGX reforms, and foreign investment inflows support PHAR's outlook.

Competitive Positioning

PHAR holds a 15% market share in Egypt's pharmaceuticals, with a diversified portfolio and strong distribution networks.

Analysis Summary

PHAR's alignment with Egypt's healthcare expansion, coupled with EGX's regional outperformance, makes it a compelling buy. Risks include regulatory changes and currency fluctuations.

Key Points
  • Strategic play on Egypt's expanding healthcare sector
  • 15% market share with diversified pharmaceutical portfolio
  • 18% growth potential backed by EGX momentum
  • Medium risk with 15.4% expected return
Recommendations